Alan Ka-Lun Wu

Alan Ka-Lun Wu

Auto-generated profile, based on publicly available information

Alan Ka-Lun Wu

Department of Clinical Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
JLJimmy Y. W. Lam
Jimmy Y. W. Lam
AWAlan K. L. Wu
Alan K. L. Wu
DNDickson C. Ngai
Dickson C. Ngai
JTJade Teng
Jade Teng
EWElsa S. Y. Wong
Elsa S. Y. Wong
Patrick WooPatrick Woo
Patrick Woo
We report the first fatal case of Campylobacter rectus infection due to a subdural empyema and ruptured mycotic intracranial aneurysm and two cases of limb-threatening C. rectus necrotizing soft tissue and bone infection and empyema thoracis that responded to amoxicillin-clavulanate and surgical debridement and drainage. All three strains were identified by 16S rRNA sequencing.

1 February 2015 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
JLJimmy Y. W. Lam
Jimmy Y. W. Lam
AWAlan K. L. Wu
Alan K. L. Wu
WLWai-Shing Leung
Wai-Shing Leung
ICIngrid Cheung
Ingrid Cheung
CTChi-Ching Tsang
Chi-Ching Tsang
Patrick WooPatrick Woo
Patrick Woo
We report here four cases of continuous ambulatory peritoneal dialysis-related peritonitis caused by three different species of Gordonia . The portal of entry was likely through Tenckhoff catheters. 16S rRNA and s ecA1 gene sequencing are so far the most reliable methods for the accurate identification of Gordonia species.

31 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
KLKenneth Siu-Sing Leung
Kenneth Siu-Sing Leung
TNTimothy Ting-Leung Ng
Timothy Ting-Leung Ng
AWAlan Ka-Lun Wu
Alan Ka-Lun Wu
MYMiranda Chong-Yee Yau
Miranda Chong-Yee Yau
HLHiu-Yin Lao
Hiu-Yin Lao
GSGilman Kit Hang SIU
Gilman Kit Hang SIU
Initial cases of COVID-19 reported in Hong Kong were mostly imported from China. However, most cases reported in February 2020 were locally-acquired infections, indicating local community transmissions. We extracted the demographic, clinical and epidemiological data from 50 COVID-19 patients, who accounted for 53.8% of the cases in Hong Kong by February 2020. Whole-genome sequencing of the SARS-CoV-2 were conducted to determine the phylogenetic relatedness and transmission dynamics. Only three (6.0%) patients required ICU admission. Phylogenetic analysis identified six transmission clusters. All locally-acquired cases harboured a common mutation Orf3a G251V and were clustered in two subclades in global phylogeny of SARS-CoV-2. The estimated time to the most recent common ancestor of local COVID-2019 outbreak was December 24, 2019 with an evolutionary rate of 3.04×10 −3 substitutions per site per year. The reproduction number value was 1.84. Social distancing and vigilant epidemiological control are crucial to the containment of COVID-19 transmission. Article summary lines: A combined epidemiological and phylogenetic analysis of early COVID-19 outbreak in Hong Kong revealed that a SARS-CoV-2 variant with ORF3a G251V mutation accounted for all locally acquired cases, and that asymptomatic carriers could be a huge public health risk for COVID-19 control.

16 October 2026 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
LHLam Kwok Ho
Lam Kwok Ho
SHSin Tsun Hei
Sin Tsun Hei
HYHo Shui Yan
Ho Shui Yan
IYIp Niki Hiu Yee
Ip Niki Hiu Yee
NCNg Wing Kei Carol
Ng Wing Kei Carol
NMNg Ming-Yen
Ng Ming-Yen
Coronavirus disease 2019 (COVID-19) has been associated with subclinical myocardial inflammation. Post-COVID-19 infection, there are concerns about subsequent heart failure and persistent myocarditis. It is unknown how COVID-19 infection compares with non-COVID-19 viral infections in terms of myocardial inflammation based on cardiovascular magnetic resonance (CMR) assessment. This prospective longitudinal study aims to determine and compare the extent and severity of myocardial involvement in patients with COVID-19 infection versus non-COVID-19 viral respiratory infections (control). Recruited recovered COVID-19 (RCOVID) patients and recovered non-COVID (non-COVID) patients from several hospitals and COVID-19-designated clinic underwent three CMR examinations for functional assessment, native T1, T2, and extracellular volume (ECV) quantification, with corroborating blood markers (NT-proBNP, white cell count, c-reactive protein, lactate dehydrogenase, and high sensitivity cardiac troponin T). CMR scans took place (i) within 2-week of confirmed recovery, (ii) 3-month, and (iii) 12-month post-recovery. Linear mixed model with Bonferroni correction was used for analysis. 152 participants were recruited, 112 RCOVID outpatients (mean age: 41.0; 58.9% female) and 40 non-COVID inpatients (mean age:45.0; 37.5% female). Non-COVID infections included influenza virus, rhinovirus/enterovirus, parainfluenza virus, respiratory syncytial virus, and human metapneumovirus. At all three time points, blood results and cardiac function parameters were not significantly different between RCOVID and non-COVID patient groups (p-value not significant). Both patient groups had no significant differences for native T1/T2 values, ECV, late gadolinium enhancement, T2 short tau inversion recovery, and overall fulfilment of the 2018 revised Lake Louise Criteria at each time points. In this prospective longitudinal study with CMR examinations, COVID-19 infection does not cause a worse myocardial inflammatory response than non-COVID-19 viral respiratory infection in terms of CMR parameters, and blood markers. During the coronavirus disease 2019 (COVID-19) outbreaks, some COVID-19 patients were incidentally found to have inflammation of the muscular layer of the heart. Healthcare professionals were concerned the inflammation will lead to heart not delivering enough blood to meet body demands (ie. heart failure) in the long run. Therefore, we designed this study to better understand the extent and severity of cardiac involvement in patients with COVID-19 by comparing them to patients with other types of viral respiratory infections, such as influenza, which we were more familiar with. We recruited two groups of patients, one group with patients recovered from COVID-19, the other group with patients recovered from other types of viral respiratory infections. For each patient, we arranged three assessments at 2 weeks, 3 months, and 12 months after their recovery respectively. During each assessment, they had blood taken and underwent a cardiovascular magnetic resonance (CMR) scan, a type of medical imaging used for assessment of heart function. 2018 revised Lake Louise Criteria (LLC) is a set of criteria for diagnosis of myocardial inflammation recommended by a group of experts. We compared the two groups of patients at each time point according to LLC, as well as their blood markers and heart function. In our study, we found that COVID-19 infection does not cause a worse heart muscle inflammatory response than other types of viral respiratory infections. This is reassuring as patients with previous COVID-19 infections will likely not develop inflammation of the heart muscle nor develop heart failure.